{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:33Z","timestamp":1792714233653,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ijpharm.2015.07.040","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T14:58:40Z","timestamp":1437922720000},"page":"86-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations"],"prefix":"10.1016","volume":"493","author":[{"given":"Sunna","family":"J\u00f3hannsd\u00f3ttir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatsawee","family":"Jansook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsteinn","family":"Loftsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2015.07.040_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workshop","volume":"5","author":"Anon","year":"2007","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1542-0124(12)70083-6","article-title":"Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international dry eye workshop","volume":"5","author":"Anon","year":"2007","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.ijpharm.2015.07.040_bib0020","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/S0039-6257(00)00205-8","article-title":"The treatment of dry eye","volume":"45","author":"Calonge","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","article-title":"Topical ophthalmic cyclosporine: pharmacology and clinical uses","volume":"54","author":"Donnenfeld","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0161-6420(85)33986-6","article-title":"Tear diluents in the treatment of keratoconjunctivitis sicca","volume":"92","author":"Gilbard","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jop.2013.0060","article-title":"\u03b3-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man","volume":"30","author":"Gudmundsdottir","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0040","first-page":"117","article-title":"Phase-solubility techniques","volume":"4","author":"Higuchi","year":"1965","journal-title":"Adv. Anal. Chem. Instrum."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics4010243","article-title":"Ophthalmic drug delivery in glaucoma \u2013 a review","volume":"4","author":"Januleviciene","year":"2012","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0050","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/jop.2013.0164","article-title":"Dorzolamide cyclodextrin nanoparticle suspension eye drops and trusopt in rabbit","volume":"30","author":"Johannesson","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/aos.12334","article-title":"Kinetics of \u03b3-cyclodextrin nanoparticle suspension eye drops in tear fluid","volume":"92","author":"Johannesson","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0060","first-page":"3150","article-title":"The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops","volume":"21","author":"Kanai","year":"1989","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0075","first-page":"1041","article-title":"Cyclosporin A: a powerful immunosuppressant","volume":"126","author":"Laupacis","year":"1982","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0080","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","article-title":"Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization","volume":"85","author":"Loftsson","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0085","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0095","doi-asserted-by":"crossref","DOI":"10.1208\/pt070104","article-title":"Determination of aqueous solubility by heating and equilibration: a technical note","volume":"7","author":"Loftsson","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/jps.20047","article-title":"Self-association of cyclodextrins and cyclodextrin complexes","volume":"93","author":"Loftsson","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2005.05.042","article-title":"Evaluation of cyclodextrin solubilization of drugs","volume":"302","author":"Loftsson","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijpharm.2009.11.035","article-title":"Self-assembled cyclodextrin aggregates and nanoparticles","volume":"387","author":"Messner","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijpharm.2011.01.011","article-title":"Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone\/cyclodextrin complexes","volume":"407","author":"Messner","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2014.08.013","article-title":"Effect of \u03b3-cyclodextrin on solubilization and complexation of irbesartan: influence of pH and excipients","volume":"474","author":"Muankaew","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/A:1015841824760","article-title":"Kinetics and mechanism of isomerization of cyclosporin A","volume":"9","author":"Oliyai","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1016231913858","article-title":"The importance of structural factors on the rate and the extent of N,O-acyl migration in cyclic and linear peptides","volume":"12","author":"Oliyai","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1444-0938.2011.00634.x","article-title":"Osmolality and tear film dynamics","volume":"95","author":"Stahl","year":"2012","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.biotechadv.2011.03.004","article-title":"Cyclosporin A \u2013 a review on fermentative production, downstream processing and pharmacological applications","volume":"29","author":"Survase","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0150","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1021\/js9704341","article-title":"Spontaneous opalescence of aqueous \u03b3-cyclodextrin solutions: complex formation or self-aggregation?","volume":"87","author":"Szente","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0155","first-page":"834","article-title":"The immunosuppressive effects of 0. 025% cyclosporin eye drops in alpha cyclodextrin on rabbit corneal allografts","volume":"96","author":"Takano","year":"1992","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0160","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1167\/iovs.11-8178","article-title":"Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema","volume":"52","author":"Tanito","year":"2011","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0165","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1021\/jm00076a002","article-title":"Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations","volume":"36","author":"Tayar","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical Review: Topical Ophthalmic Use of Cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul. Immunol. Inflammation"},{"key":"10.1016\/j.ijpharm.2015.07.040_bib0175","doi-asserted-by":"crossref","first-page":"194848","DOI":"10.1100\/2012\/194848","article-title":"An overview on dry eye treatment: approaches for cyclosporin A delivery","volume":"2012","author":"Yavuz","year":"2012","journal-title":"Sci. World J."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T17:20:22Z","timestamp":1537464022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517315300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0378517315300594"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.07.040","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}